News & Events

News

Nexstim offers targeted and effective therapies and diagnostics for challenging brain diseases and disorders. Our technology is solidly grounded in scientific and clinical research. We closely collaborate with key opinion leaders who, like us, believe noninvasive brain stimulation harnesses the brain's own healing power—neuroplasticity. Nexstim is helping patients—and their families—get back the life they feared they had lost.

Customers and Trade

Research and Development

Nexstim Plc: Nexstim Plc publishes prospectus regarding EUR 5.2 million rights issue and new information regarding previous profit forecast

Nexstim Oyj: EUR 5.2 million rights issue Of Nexstim Oyj

Nexstim Plc: Decisions of the Board of Directors regarding Board Committees and issuance of shares under the restricted share unit plan

Nexstim Plc: Resolutions of the Annual General Meeting of Shareholders

FDA clears a new, more rapid treatment protocol for Nexstim’s NBT® system when treating patients with major depressive disorder

Nexstim Plc is planning a Rights Issue

Nexstim Plc: Invitation to the Annual General Meeting

Nexstim Plc Publishes 2018 Annual Report

Nexstim Plc Financial Statements Release 2018

Nexstim Plc Postpones its 2018 Full Year Results Release to Monday 4 March 2019

Notice of Nexstim Plc 2018 Full Year Results

Registration of the quantity of shares in Nexstim Plc